AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 528504: Hexadecane, 3-decyl

Chemical compound data from PubChem database. IUPAC Name: 11-ethyltetracosane. Molecular Formula: C26H54. Molecular Weight: 366.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.

Tags: chemistry, compound, pubchem, research, science
Organization: U.S. Department of Health & Human Services
National Mental Health Services Survey (N-MHSS): 2017, Data On Mental Health Treatment Facilities

This report presents findings from the 2017 National Mental Health Services Survey (N-MHSS) conducted from March 2017 through December 2017. The N-MHSS collects information from all known facilities in the United States, both public and private, that provide mental health treatment services to people with mental illness.3 The Center for Behavioral Health Statistics and Quality (CBHSQ) of the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services, plans and directs the N-MHSS.The N-MHSS provides a mechanism for quantifying the dynamic character and composition

Tags: behavioral-health, mental-health-facilities, mental-health-services, samhsa, treatment-facilities
Organization: U.S. Department of Health & Human Services
Stage-specific changes in fetal thymocyte proliferation during the CD4

Background
          The function of the thymic microenvironment is to promote thymocyte maturation, in part via regulation of thymocyte proliferation and cell death. Defects in fetal thymic epithelial cell (TEC) development and function, and therefore in the formation of a functional microenvironment, can be caused either directly by TEC differentiation defects or indirectly by defective thymocyte maturation. In this paper we studied fetal thymocyte proliferation during the early transition from the CD3-4-8- (triple negative, TN) to CD4+8+ (double positive, DP) stages. We compared wild type mice with Rag1-/- mice and with Hoxa3+/-Pax1-/- compound mutant mice, which have blocks at different stages of thymocyte development.
        
        
          Results
          Wild type fetal and adult thymus showed stage-specific differences in the proliferation profiles of developing thymocytes, with fetal stages showing generally higher levels of proliferation. The proliferation profile of fetal thymocytes from Rag1-/- mutants also had stage-specific increases in proliferation compared to wild type fetal thymocytes, in contrast to the lower proliferation previously reported for thymocytes from adult Rag1-/- mutants. We have previously shown that Hoxa3+/-Pax1-/- mice have abnormal fetal TEC development, resulting in increased apoptosis at the TN to DP transition and decreased DP cell numbers. Fetal thymocytes from Hoxa3+/-Pax1-/- compound mutants had increased proliferation, but fewer proliferating cells, at the DP stage. We also observed a decrease in the level of the cytokines IL-7 and SCF produced by Hoxa3+/-Pax1-/-TECs.
        
        
          Conclusion
          Our results indicate complex and stage-specific effects of abnormal TEC development on thymocyte proliferation.

Tags: cd4-cd8-stages, fetal-thymocytes, nih, thymic-microenvironment, thymocyte-proliferation
Organization: U.S. Department of Health & Human Services
Effect of mivacurium 200 and 250 μg/kg in infants during isoflurane anesthesia: a randomized controlled trial [ISRCTN07742712]

Background
          Infants usually respond differently to a neuromuscular relaxant compared to children or adults. Isoflurane is commonly used as an anesthetic gas in infants. In an RCT design, we investigated whether a dose of mivacurium 250 μg/kg results in faster onset of action than 200 μg/kg in infants under isoflurane anesthesia. Spontaneous recovery times and cardiovascular response were also evaluated.
        
        
          Methods
          Twenty-four low surgical risk children, aged 6–24 months, undergoing an elective surgery and requiring tracheal intubation were selected. After anesthetic induction, patients randomly received an iv bolus dose of mivacurium 200 or 250 μg/kg. After maximal relaxation, the patient was intubated. Isoflurane was administered to maintain anesthetic level during the surgical procedure. Neuromuscular function was monitored by accelerometry (TOF-Guard) at the adductor pollicies. The first twitch (T) of the TOF and the T4/T1 were measured. The time-course of heart rate and systolic and diastolic blood pressure were analysed by transforming them into their respective areas under the curve.
        
        
          Results
          Mivacurium 250 μg/kg produced a maximal T block faster than 200 μg/kg, i.e. 2.4 ± 1.1 vs. 3.5 ± 1.4 min (p < 0.05). Spontaneous recovery times were similar in both groups. Heart rate was similar between doses while systolic and diastolic blood pressures were lower with the higher dose (p < 0.05). Flushing was observed in two cases, one in each group.
        
        
          Conclusions
          The maximal effect of mivacurium 250 μg/kg, in infants under isoflurane anesthesia, was present one minute faster than 200 μg/kg. However, it produced a significant cardiovascular response.

Tags: infant-anesthesia, isoflurane-anesthesia, mivacurium-dosage, neuromuscular-blockade, nih
Organization: U.S. Department of Health & Human Services
Activation of the kinin system in the ovary during ovulation: Role of endogenous progesterone

Background
          Previous work by our group and others has implicated a role for kinins in the ovulatory process. The purpose of the present study was to elucidate whether endogenous progesterone, which is an intraovarian regulator of ovulation, might be responsible for induction of the kinin system in the ovary during ovulation. The gonadotropin-primed immature rat was used as the experimental model, and the role of endogenous progesterone was explored using the antiprogestin, RU486.
        
        
          Results
          The results of the study revealed that RU486 treatment, as expected, significantly attenuated ovulation. Activity of the kinin-generating enzyme, kallikrein, was elevated in the ovary in control animals prior to ovulation with peak values observed at 4 h post hCG, only to fall to low levels at 10 h, with a recovery at 20 h post hCG. RU486 treatment had no significant effect on ovarian kallikrein activity as compared to the control group. Total ovarian kininogen levels in control animals increased significantly at 12–14 h after hCG – coinciding with initiation of ovulation. Thereafter, ovarian kininogen levels fell to low levels at 20 h, only to show a rebound from 24–38 h post-hCG. RU486 treatment had no significant effect on the rise of total ovarian kininogen levels from 12–14 h after hCG; however, from 30–40 h post hCG, RU486-treated animals had significantly higher total ovarian kininogen levels versus control animals, suggesting that endogenous progesterone may act to restrain elevations of kininogens in the post-ovulatory ovary. This robust elevation of ovarian kininogen levels by RU486 was found to be primarily due to an increase in T-kininogen, which is a potent cysteine protease inhibitor.
        
        
          Conclusions
          Taken as a whole, these results suggest that endogenous progesterone does not regulate kallikrein activity or kininogens prior to ovulation, but may provide a restraining effect on T-kininogen levels in the post-ovulatory ovary.

Tags: kinin-system, nih, ovarian-kallikrein, ovulation-process, progesterone-regulation
Organization: U.S. Department of Health & Human Services
Compound 525356: 2,2-Dimethyl-5,6-dithiaheptane

Chemical compound data from PubChem database. IUPAC Name: 3,3-dimethyl-1-(methyldisulfanyl)butane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.

Tags: chemistry, compound, pubchem, research, science
Organization: U.S. Department of Health & Human Services
Publications Using SAMHSA DataComparison of the 2002-2004 and 2010-2012 Model-Based Substate Estimates

Publications Using SAMHSA DataComparison of the 2002-2004 and 2010-2012 Model-Based Substate Estimates

Tags: behavioral-health, mental-health, samhsa, small-area-estimation, substance-use
Organization: U.S. Department of Health & Human Services
Few Substance Abuse Treatment Admissions Are Referred by Employers

This is a Treatment Episode Data Set (TEDS) spotlight showing that few substance abuse treatment admissions are referred by employers in 2011. The Treatment Episode Data Set (TEDS) is a national data system of annual admissions to substance abuse treatment facilities. TEDS received treatment admission records from 46 states, the District of Columbia, and Puerto Rico in 2011.

Tags: employer-referrals, samhsa, substance-abuse-treatment, teds-data, treatment-admissions
Organization: U.S. Department of Health & Human Services
2017 Uniform Reporting System (URS) Table for South Dakota

This is the 2017 Uniform Reporting System (URS) Output Tables for South Dakota. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.

Tags: block-grant, mental-health-services, noms-measures, samhsa, south-dakota
Organization: U.S. Department of Health & Human Services
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty

Background
          Although all patients undergoing total joint arthroplasty are subjected to similar risk factors that predispose to thromboembolism, only a subset of patients develop this complication. The objective of this study was to determine whether a specific genetic profile is associated with a higher risk of developing a postoperative thromboembolic complication. Specifically, we examined if the Factor V Leiden (FVL) mutation or the deletion polymorphism of the angiotensin-converting enzyme (ACE) gene increased a patient's risk for postoperative thromboembolic events. The FVL mutation has been associated with an increased risk of idiopathic thromboembolism and the deletion polymorphism of the ACE gene has been associated with increased vascular tone, attenuated fibrinolysis and increased platelet aggregation.
        
        
          Methods
          The presence of these genetic profiles was determined for 38 patients who had a postoperative symptomatic pulmonary embolus or proximal deep venous thrombosis and 241 control patients without thrombosis using molecular biological techniques.
        
        
          Results
          The Factor V Leiden mutation was present in none of the 38 experimental patients and in 3% or 8 of the 241 controls (p = 0.26). Similarly there was no difference detected in the distribution of polymorphisms for the ACE gene with the deletion-deletion genotype present in 36% or 13 of the 38 experimental patients and in 31% or 74 of the 241 controls (p = 0.32).
        
        
          Conclusions
          Our results suggest that neither of these potentially hypercoaguable states are associated with an increased risk of symptomatic thromboembolic events following total hip or knee arthroplasty in patients receiving pharmacological thromboprophylaxis.

Tags: ace-polymorphism, factor-v-leiden, joint-arthroplasty, nih, thromboembolism-risk
Organization: U.S. Department of Health & Human Services
Results from the 2013 National Survey on Drug Use and Health: Mental Health Detailed Tables

These detailed tables present results pertaining to mental health from the 2013 National Survey on Drug Use and Health (NSDUH), an annual survey of the civilian, noninstitutionalized population of the United States aged 12 years old or older. The detailed tables present national estimates of the prevalence of past year mental disorders and past year mental health service utilization for youths aged 12 to 17 and adults aged 18 or older. Among adults, estimates presented include rates and numbers of persons with any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), and mental health service utilization. Estimates for youths include MDE, treatment for depression (among youths with MDE), and mental health service utilization. Measures related to the co-occurrence of mental disorders with substance use or with substance use disorders also are presented for both adults and youths. Results are provided by age group, gender, race/ethnicity, education level, employment status, county type, poverty level, insurance status, overal health, and geographic area. Comparisons are made between 2012 and 2011.

Tags: major-depressive-episode, mental-health-survey, samhsa, serious-mental-illness, substance-use-co-occurrence
Organization: U.S. Department of Health & Human Services
Instructions to update the SAMHSA SMI and SED Estimates URS Table 1: Number of Adults with Serious Mental Illness, age 18 and older, by State, 2015

These instructions explain how to update the 2015 Substance Abuse and Mental Health Services Administration (SAMHSA) Serious Mental Illness (SMI) and Serious Emotional Disturbances (SED) estimates. This includes obtaining the latest population data by state from the U.S. Census Bureau as well as the calculations and methodology necessary to create updated estimates.

Tags: adult-mental-health, samhsa, serious-mental-illness, smi-estimates, state-level-data
Organization: U.S. Department of Health & Human Services
2010 State Profile — Minnesota

This state profile includes data from facilities in Minnesota that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Minnesota. In Minnesota, 308 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 15,001 clients in substance abuse treatment on March 31, 2010. The survey response rate in Minnesota was 97.2%.

Tags: alcohol-drug-abuse, minnesota, n-ssats, samhsa, substance-abuse-treatment
Organization: U.S. Department of Health & Human Services
Kansas City, MO-KS

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Kansas City, MO-KS metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Kansas City metro area, Missouri, and the U.S. overall.

Tags: kansas-city, major-depression, nsduh, samhsa, substance-use
Organization: U.S. Department of Health & Human Services
Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight

The Arterial Revascularization Therapy Study (ARTS) and the Stent or Surgery (SoS) trial each randomized patients with multivessel disease to either stenting or bypass surgery. The ARTS showed no difference in mortality between the two strategies, other than in diabetic patients, who fared better with surgery. The SoS trial demonstrated increased mortality in the stent arm, a difference that was not attributable to diabetes. Both trials found that the rates of repeat revascularization were lower with surgery, although the rate with stenting was much lower than had been seen in previous trials of angioplasty. Use of antiplatelet therapy such as intravenous glycoprotein IIb/IIIa inhibitors, especially with their pronounced effects in diabetics and in those with multivessel disease, could potentially equalize the playing field or perhaps even tip the balance in favor of percutaneous intervention.

Tags: arterial-revascularization, multivessel-disease, nih, pci-vs-cabg, stent-outcomes
Organization: U.S. Department of Health & Human Services
PKQuest: capillary permeability limitation and plasma protein binding – application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics

Background
          It is generally assumed that the tissue exchange of antibiotics is flow limited (complete equilibration between the capillary and the tissue water). This assumption may not be valid if there is a large amount of plasma protein binding because the effective capillary permeability depends on the product of the intrinsic capillary permeability (PS) and the fraction of solute that is free in the blood (fwB). PKQuest, a new generic physiologically based pharmacokinetic software routine (PBPK), provides a novel approach to modeling capillary permeability in which the only adjustable parameter is the PS of muscle.
        
        
          Methods
          All the results were obtained by applying PKQuest to previously published human pharmacokinetic data.
        
        
          Results
          The PKQuest analysis suggests that the highly protein bound antibiotics dicloxacillin and ceftriaxone have a significant capillary permeability limitation. The human muscle capillary PS of inulin, dicloxacillin and ceftriaxone was 0.6, 13 and 6 ml/min/100 gm, respectively. The ceftriaxone protein binding is non-linear, saturating at high plasma concentrations. The experimental ceftriaxone data over a wide range of intravenous inputs (0.15 to 3 gms) was well described by PKQuest. PKQuest is the first PBPK that includes both permeability limitation and non-linear binding.
        
        
          Conclusions
          Because of their high degree of plasma protein binding, dicloxacillin and ceftriaxone appear to have a diffusion limited exchange rate between the blood and tissue and are not flow limited as had been previously assumed. PKQuest and all the examples are freely available at .

Tags: antibiotics, capillary-permeability, nih, pharmacokinetics, protein-binding
Organization: U.S. Department of Health & Human Services
Compound 525099: 1,3-Dichloroisopropyl isopentanoate

Chemical compound data from PubChem database. IUPAC Name: 1,2-dichloropropan-2-yl 3-methylbutanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.

Tags: chemistry, compound, pubchem, research, science
Organization: U.S. Department of Health & Human Services
Children’s Bureau Regional Program Managers

CBRegion1@acf.hhs.gov - please use for grantee plan submissionsAmy LockhartAmy.Lockhart@acf.hhs.govJFK Federal Building, Rm. 200015 Sudbury StreetBoston, MA 02203(617) 565-1135States:  Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont

CBRegion2@acf.hhs.gov - please use for grantee plan submissionsShari BrownShari.Brown@acf.hhs.gov26 Federal Plaza, Rm. 4114New York, NY10278(646) 905-8217States and Territories:  New Jersey, New York, Puerto Rico, Virgin Islands

CBRegion3@acf.hhs.gov - please use for grantee plan submissionsEvan SteelEvan.Steel@acf.hhs.govThe Strawbridge Building801 Market StreetPhiladelphia, PA 19107-3134(215) 861-4013States:  Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia

CBRegion4@acf.hhs.gov - please use for grantee plan submissionsDianne KellyDianne.Kelly@acf.hhs.gov61 Forsyth Street SW, Ste. 4M60Atlanta, GA 30303-8909(404) 562-2781States: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee

CBRegion5@acf.hhs.gov - please use for grantee plan submissionsCindy LowderCindy.Lowder@acf.hhs.govRalph H. Metcalfe Federal Building77 West Jackson Boulevard, 21st FloorChicago, IL 60604(312) 886-4918States: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin

CBRegion6@acf.hhs.gov - please use for grantee plan submissionsCory McCarrellCory.McCarrell@acf.hhs.gov1301 Young Street, Suite 106-1060Dallas, TX 75202-5433(214) 767-1971States: Arkansas, Louisiana, New Mexico, Oklahoma, Texas

CBRegion7@acf.hhs.gov - please use for grantee plan submissionsKendall DarlingKendall.Darling@acf.hhs.govFederal Office Building, Room 349601 E. 12th StreetKansas City, MO 64106(816) 426-2262States: Iowa, Kansas, Missouri, Nebraska

CBRegion8@acf.hhs.gov - please use for grantee plan submissionsMarilyn KennersonMarilyn.Kennerson@acf.hhs.gov1961 Stout Street, 8th FloorByron Rogers Federal BuildingDenver, CO 80294-3538(303) 844-1163States: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming

CBRegion9@acf.hhs.gov - please use for grantee plan submissionsSharon KingSharon.King@acf.hhs.gov90 7th Street - Ste 9-300San Francisco, CA 94103(415) 437-8513States and Territories: Arizona, California, Hawaii, Nevada, Outer Pacific—American Samoa Commonwealth of the Northern Marianas, Federated States of Micronesia (Chuuk, Pohnpei, Yap), Guam, Marshall Islands, Palau

CBRegion10@acf.hhs.gov - please use for grantee plan submissionsNadia NijimNadia.Nijim@acf.hhs.gov701 Fifth Avenue, Suite 1600, MS-73Seattle, WA 98104(206) 615-3682States: Alaska, Idaho, Oregon, Washington

Metadata-only record linking to the original dataset. Open original dataset below.

Tags: child, contact, grant, scope, social
Organization: U.S. Department of Health & Human Services
Compound 528458: 1-Pentadecene, 7-methyl

Chemical compound data from PubChem database. IUPAC Name: 7-methylpentadec-1-ene. Molecular Formula: C16H32. Molecular Weight: 224.42. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.

Tags: chemistry, compound, pubchem, research, science
Organization: U.S. Department of Health & Human Services
Compound 528401: A-Fructopyranose, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[[2,3,4,5-tetrakis(trimethylsilyloxy)oxan-2-yl]methoxy]silane. Molecular Formula: C21H52O6Si5. Molecular Weight: 541.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.

Tags: chemistry, compound, pubchem, research, science
Organization: U.S. Department of Health & Human Services
2018 Uniform Reporting System (URS) Table for Northern Mariana Islands

This is the 2018 Uniform Reporting System (URS) Output Tables for Northern Mariana Islands. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.

Tags: mental-health-services, noms-measures, northern-mariana-islands, samhsa, services
Organization: U.S. Department of Health & Human Services
Compound 528471: 1-Undecene, 6,10-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 6,10-dimethylundec-1-ene. Molecular Formula: C13H26. Molecular Weight: 182.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.

Tags: chemistry, compound, pubchem, research, science
Organization: U.S. Department of Health & Human Services